Muayad Merza

Followers

Following

Public Views

Muayad Aghali Merza (MD)Dean, College of Pharmacy, University of Duhok, Duhok, Kurdistan RegionMBChB, MSc, PhD, FID - Assistant Professor in Infectious DiseasesClinician and Researcher Department of Internal Medicine, Azadi Teaching Hospital

less

John Barry

Queen's University Belfast

David Seamon

Kansas State University

Armando Marques-Guedes

UNL - New University of Lisbon

Gary Feinman

Field Museum

naveen noronha

Visvesvaraya Technological University

Iain Staffell

Imperial College London

Isad Saric

University of Sarajevo

Richard Crawford

The University of Texas at Austin

Chandramouli Padmanabhan

IIT Madras

Umit Unver

Yalova University

Interests

Uploads

Papers by Muayad Merza

The Potential Risk of Reduced Serum Cholinesterase Activity in COVID-19 Patients Suffering From Cytokine Storm

Curēus, May 16, 2024

Several blood biochemical parameters are used to biomonitor coronavirus disease 2019 , caused by ... more Several blood biochemical parameters are used to biomonitor coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Reduced serum cholinesterase (ChE) has been suggested to be a predictive indicator of the severity and outcome of COVID-19 infection. This study aimed to examine serum ChE activity in hospitalized and terminally ill COVID-19 patients with cytokine storm and evaluate the enzyme for the in vitro ChE-inhibitory activity of the organophosphate dichlorvos. We determined the serum ChE activity, electrometrically, among hospitalized COVID-19-cytokine storm patients and their non-cytokine storm counterparts. Aliquots of serum samples from healthy volunteers, COVID-19-cytokine storm patients, and non-cytokine storm COVID-19 patients were pooled separately. They were incubated in vitro for 10 minutes with dichlorvos at 0.25 or 0.5 μM. Serum samples from the three groups were subjected to ChE inhibition temporally (5-60 minutes) by 0.25 μM dichlorvos to evaluate the kinetics of enzyme inhibition using steady-state kinetics. Of the 165 hospitalized patients with COVID-19, 33 (20%) suffered from the cytokine storm. Serum ChE activity of female COVID-19 patients with cytokine storm was significantly lower than that of the noncytokine storm counterparts. Risk analysis of reduced serum ChE activity (≥20%) among the 33 COVID-19 patients with cytokine storm compared to 111 non-cytokine storm COVID-19 patients revealed that the former were significantly at risk of reduced enzyme activity. In vitro, dichlorvos at 0.25 μM and 0.5 μM significantly inhibited serum ChE activity in all the groups. The COVID-19-cytokine storm group was the least affected. Dichlorvos at 0.25 μM progressively (5-60 minutes) inhibited serum ChE activity. The inhibition kinetic parameters in COVID-19-cytokine storm patients showed a decrease in the half-life of inhibition (14.54%), inhibition rate (51.46%), and total inhibition time (14.55%). Reduced serum ChE in COVID-19 patients with cytokine storm could be adopted as a potential additional laboratory examination tool for bedside risk assessment. The in vitro inhibition profile of serum ChE activity by dichlorvos in COVID-19-cytokine storm patients suggests reduced susceptibility of the enzyme to inhibition. The response of COVID-19 patients to ChE-inhibiting medications should be cautiously evaluated with prior in vitro tests.

Muayad Merza

Related Authors

Uploads

Papers by Muayad Merza

Log In